Luteinizing hormone supplementation and cumulative live birth rate in assisted reproductive technology cycles among women of advanced reproductive age
By
Leizhen Xia
Wenting Xia
Lifeng Tian
Jialyu Huang
Houyang Chen
Li Cai
Leixiang Xia
Yan Zhao
Wei Gao
June 17, 2026
Clinical Scorecard: Impact of Luteinizing Hormone Supplementation on Cumulative Live Birth Rates in Assisted Reproductive Technology for Older Women
At a Glance
Category Detail
Condition Key Mechanisms Target Population Women aged ≥35 years undergoing ART Care Setting
Key Highlights
Cumulative live birth rate (CLBR) was higher in the rFSH+rLH group compared to rFSH alone (61.31% vs. 51.48%, P = 0.036). Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Be aware of the potential for increased gonadotropin doses and longer stimulation duration with certain regimens. Counsel patients on the risks associated with increased gonadotropin doses. Patient & Prescribing Data
Women of advanced reproductive age undergoing ART
Recombinant LH supplementation may improve cumulative live birth rates compared to rFSH alone.
Clinical Best Practices
Utilize propensity score matching to balance baseline characteristics in ART studies. Focus on cumulative live birth rate as a primary outcome in ART evaluations. Consider individual patient characteristics when selecting gonadotropin regimens. Further research is needed to confirm the benefits of rLH supplementation. Related Resources & Content
